Additionally, exploring combined intervention strategies involving the PKA/EPAC pathway with other key metabolic pathways is necessary to overcome the vicious cycle between diabetes and lipid metabolism disorders and to develop tissue-specific delivery systems to achieve precise targeting of key tissues, such as the liver and islets, by drugs, thereby enhancing the therapeutic effect and reducing side effects. The gene discussed is RAPGEF3; the disease is diabetes mellitus.